Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

- PMLiVE

Shire launches rare disease website

Hereditary angioedema sitesupports its Me, Not HAE campaign

UK flag

London life science growth boosted by Takeda

Japanese firm adds to recent surge in pharma spending in the capital

- PMLiVE

Takeda strengthens leadership team with business unit director

Craig Adkins takes up the position after being at the firm for ten years

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

Shire Basingstoke

Shire enters research partnership for rare eye disease

Will work with Foundation Fighting Blindness on treatment for adRP

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

Shire Basingstoke

Silver lining as Shire rare disease programme hits a setback

Alagille syndrome candidate fails to meet phase II targets

Shire Basingstoke

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Shire Basingstoke

Shire links with US hospital for rare disease research

Willwork with Cincinnati Children's Hospital Medical Centre novel therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links